Product CommercializationXOLREMDI sales increased significantly, surpassing estimates, due to commercialization progress and inventory build.
Revenue And EarningsThe company reported total revenue of $28.8M, significantly exceeding the consensus estimate of $11.6M, and achieved a net income of $0.04 per share, surpassing the consensus estimated net loss of $0.12 per share.
Strategic PartnershipsX4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in future.